Fluzoparib, Camrelizumab, and Temozolomide for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of three drugs (Fluzoparib, Camrelizumab, and Temozolomide) for people with advanced melanoma that has spread or cannot be removed by surgery. It is for those who have a specific genetic change (HR or SF3B1 mutation) and have not been treated with a PARP inhibitor before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (stage III or IV) that cannot be removed by surgery or has spread
- You have a specific genetic change called HR or SF3B1 mutation in your tumor
- You have not been treated with a PARP inhibitor drug before
- You are generally able to perform daily activities (ECOG score 0 or 1)
- You have recovered from side effects of previous treatments
- You are willing to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This early-phase trial studies a combination treatment—an interferon-type medicine, an immune checkpoint antibody, and a targeted anti-angiogenesis pill—for advanced melanoma that cannot be removed with surgery. The goal is to see whether this combination can shrink tumors and be tolerated, and to learn the best way to treat this stage of melanoma.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.